{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"Lymph node response defined as greater than or equal to 50% decrease in the SPD of target lymph nodes","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"3 years","title":"Lymph Node Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}